Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yunzhi capsules (云芝菌胶囊) is an approved traditional Chinese medicine (TCM) product developed by Jiangsu Shenhua Pharmaceutical. It is derived from the medicinal mushroom *Coriolus versicolor* (also known as *Trametes versicolor* or Turkey Tail). The primary active components are polysaccharides, specifically polysaccharide-K (PSK) and polysaccharide-peptide (PSP), which function as immunomodulators. These compounds enhance the activity of T-lymphocytes, B-lymphocytes, macrophages, and natural killer (NK) cells. Yunzhi capsules are primarily indicated as an adjuvant therapy for various cancers (to mitigate the side effects of chemotherapy and radiotherapy), chronic hepatitis, and recurrent respiratory tract infections by boosting the host's immune response.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yunzhi capsules.